BALATON

A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion.

COMINO

A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion

PHOTON

A randomized, double-masked active-controlled Phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema.

PAVILION

A Phase III, multicenter, randomized study of the efficacy, safety, and pharmacokinetics of the port delivery system with diabetic retinopathy.

NGM621-GA-201

A Phase 2 multicenter, randomized, double-masked, sham-controlled study of the safety and efficacy of intravitreal injections of MGM621 in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

CANDELA

A randomized, single-masked, active-controlled Phase 2 study of the safety, tolerability, and efficacy of repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration.

GALLEGO

A Phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration.

GRAYBUG

A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a long-acting intravitreal sunitinib malate depot formulation (GB-102) compared to intravitreal aflibercept in subjects with neovascular (wet) age-related macular degeneration

XPLORE

A Phase III, double-blind, parallel group, multicenter study to compare the efficacy and safety of Xlucane versus Lucentis in patients with neovascular age-related macular degeneration.

PAGODA

A Phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab in patients with diabetic macular edema

RHINE (closed to enrollment)

A Phase III, multicenter, randomized, double-masked active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.

ARCHWAY (closed to enrollment)

A Phase III, multicenter, randomized, visual assessor-masked, active-comparator study of efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.

PORTAL (closed to enrollment)

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.

TENAYA (closed to enrollment)

A Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and Safety of faricimab in patients with neovascular age-related macular degeneration.

CHENGDU (closed to enrollment)

A Phase III, multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with neovascular age-related macular degeneration (AMD) (PANDA-2)

DERBY (closed to enrollment)

A Phase III, multi-center, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

OPTHEA (closed)

A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD).

CEDAR (closed)

A Phase III study to assess the safety and efficacy of abicipar compared with ranibizumab in treatment-naive patients with neovascular age-related macular degeneration.

LADDER (closed)

A Phase II study to investigate the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

PANORAMA (closed)

A Phase III, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy.

AVENUE (closed)

A Phase II study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with neovascular age-related macular degeneration.

GX 29455 (closed)

A Phase II sham injection-controlled exposure-response study of lampalizumab intravitreal injections administered every two weeks or every four weeks for geographic atrophy.

OLEi GX28198 (closed)

A Phase III multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab (FCFD4514S) in patients with geographic atrophy who have completed Genentech-sponsored lampalizumab studies.

ONYX (closed)

A randomized, double-masked, active-controlled phase 2 study of the eficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration.